研究者業績
Profile Information
- Affiliation
- School of Health Sciences, Fujita Health University
- Degree
- 博士(医療科学)(Mar, 2025, 藤田医科大学)
- Researcher number
- 31022543
- ORCID ID
https://orcid.org/0009-0000-1721-939X- J-GLOBAL ID
- 202501014214121844
- researchmap Member ID
- R000087383
Research History
3-
Oct, 2025 - Present
-
Apr, 2025 - Present
-
Apr, 2022 - Mar, 2025
Education
3-
Apr, 2022 - Mar, 2025
-
Apr, 2020 - Mar, 2022
-
Apr, 2016 - Mar, 2020
Awards
1-
Jun, 2021
Papers
7-
British Journal of Pharmacology, 182(7) 1466-1486, Dec 10, 2024 Peer-reviewedBackground and Purpose Alterations in tryptophan‐kynurenine (TRP‐KYN) pathway are implicated in major depressive disorder (MDD). α7 nicotinic acetylcholine (α7nACh) receptor regulates the hypothalamic–pituitary–adrenal (HPA) axis. We have shown that deficiency of kynurenine 3‐monooxygenase (KMO) induces depression‐like behaviour via kynurenic acid (KYNA; α7nACh antagonist). In this study, we investigated the involvement of the TRP‐KYN pathway in stress‐induced behavioural changes and the regulation of the HPA axis. Experimental Approach Mice were exposed to chronic unpredictable mild stress (CUMS) and subjected to behavioural tests. We measured TRP‐KYN metabolites and the expression of their enzymes in the hippocampus. KMO heterozygous mice were used to investigate stress vulnerability. We also evaluated the effect of nicotine (s.c.) on CUMS‐induced behavioural changes and an increase in serum corticosterone (CORT) concentration. Key Results CUMS decreased social interaction time but increased immobility time under tail suspension associated with increased serum corticosterone concentration. CUMS increased KYNA levels via KMO suppression with microglial decline in the hippocampus. Kmo+/− mice were vulnerable to stress: they exhibited social impairment and increased serum corticosterone concentration even after short‐term CUMS. Nicotine attenuated CUMS‐induced behavioural changes and increased serum corticosterone concentration by inhibiting the increase in corticotropin‐releasing hormone. Methyllycaconitine (α7nACh antagonist) inhibited the attenuating effect of nicotine. Conclusions and Implications CUMS‐induced behavioural changes and the HPA axis dysregulation could be induced by the increased levels of KYNA via KMO suppression. KYNA plays an important role in the pathophysiology of MDD as an α7nACh antagonist. Therefore, α7nACh receptor is an attractive therapeutic target for MDD.
-
Neurochemistry International, 180 105858-105858, Nov, 2024 Peer-reviewed
-
Neuropsychopharmacology, 50(5) 739-750, Oct 11, 2024 Peer-reviewedLead authorAbstract Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors, social deficits, and cognitive impairments. Maternal use of valproic acid (VPA) during pregnancy is associated with an increased risk of ASD in offspring. The prevailing pathophysiological hypothesis for ASD involves excitation/inhibition (E/I) imbalances and serotonergic dysfunction. Here, we investigated the association between glutamatergic-serotonergic neuronal interactions and ASD-like behaviors in mice exposed to prenatal VPA. Prenatal VPA exposure induced excessive repetitive self-grooming behavior and impaired social behavior and object recognition memory in young adult period. Prenatal VPA mice showed hyper-glutamatergic function (increase in basal extracellular glutamate levels and CaMKII phosphorylation) and hypo-serotonergic function (decrease in 5-hydroxyindoleacetic acid and stimulation-induced serotonin [5-HT] release, but an increase in 5-HT transporter expression) in the prefrontal cortex. Treatment with a low-affinity NMDA receptor antagonist (memantine), a selective 5-HT reuptake inhibitor (fluoxetine), and a 5-HT1A receptor agonist (tandospirone) attenuated both the increase in CaMKII phosphorylation and ASD-like behavior of prenatal VPA mice. Opto-genetic activation of the serotonergic neuronal system attenuated impairments in social behavior and object recognition memory in prenatal VPA mice. WAY-100635—a 5-HT1A receptor antagonist—antagonized the effect of fluoxetine on impaired social behavior and object recognition memory. These results suggest that E/I imbalance and ASD-like behavior are associated with hypo-serotonergic receptor signaling through 5-HT1A receptors in prenatal VPA mice.
-
Methods in Molecular Biology, 331-340, Apr 18, 2024 Lead author
-
British Journal of Pharmacology, 180(18) 2393-2411, May 17, 2023 Peer-reviewedBackground and Purpose High salt (HS) intake has been associated with hypertension and cognitive impairment. It is well known that the angiotensin II (Ang II)‐AT1 receptor and prostaglandin E2 (PGE2)‐EP1 receptor systems are involved in hypertension and neurotoxicity. However, the involvement of these systems in HS‐mediated hypertension and emotional and cognitive impairments remains unclear. Experimental Approach Mice were loaded with HS solution (2% NaCl drinking water) for 12 weeks, and blood pressure was monitored. Subsequently, effects of HS intake on emotional and cognitive function and tau phosphorylation in the prefrontal cortex (PFC) and hippocampus (HIP) were investigated. The involvement of Ang II‐AT1 and PGE2‐EP1 systems in HS‐induced hypertension and neuronal and behavioural impairments was examined by treatment with losartan, an AT1 receptor blocker (ARB), or EP1 gene knockout. Key Results We demonstrate that hypertension and impaired social behaviour and object recognition memory following HS intake may be associated with tau hyperphosphorylation, decreased phosphorylation of Ca2+/calmodulin‐dependent protein kinase II (CaMKII), and postsynaptic density protein 95 (PSD95) expression in the PFC and HIP of mice. These changes were blocked by pharmacological treatment with losartan or EP1 receptor gene knockout. Conclusions and Implications Our findings suggest that the interaction of Ang II‐AT1 receptor and PGE2‐EP1 receptor systems could be novel therapeutic targets for hypertension‐induced cognitive impairment.
Presentations
6Teaching Experience
3-
Apr, 2025 - Present基礎医学実習 (藤田医科大学)
-
Apr, 2025 - Presentクリニカルトライアル (藤田医科大学)
-
Apr, 2023 - Mar, 2025医療コーディネート概論 (藤田医科大学)